SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1537 6591 "

Sökning: L773:1537 6591

  • Resultat 51-60 av 319
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
51.
  • Christensson, Bertil, et al. (författare)
  • Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission
  • 2000
  • Ingår i: Clinical Infectious Diseases. - : Oxford University Press (OUP). - 1537-6591 .- 1058-4838. ; 30:3, s. 585-586
  • Tidskriftsartikel (refereegranskat)abstract
    • Twenty-eight cases of hepatitis C virus (HCV) infection were identified in children in a pediatric oncology ward during 2 nosocomial outbreaks. HCV infection spontaneously cleared in 6 patients (21%). Eleven patients with persistent HCV viremia who had malignant diseases in remission after treatment were given a 48-week course of combined therapy with interferon-alpha (5x106 U 3 times weekly) and oral ribavirin (15 mg/kg/d). Seven (64%) of the 11 patients had sustained virological responses 6 and 12 months after cessation of therapy. Side effects were common but generally were mild or moderate.
  •  
52.
  • Chu, Vivian H, et al. (författare)
  • Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database.
  • 2004
  • Ingår i: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. - : Oxford University Press (OUP). - 1537-6591. ; 39:10, s. 1527-30
  • Tidskriftsartikel (refereegranskat)abstract
    • Using a large cohort of patients from the International Collaboration on Endocarditis Merged Database, we compared coagulase-negative staphylococcal (CoNS) native-valve endocarditis (NVE) to NVE caused by more common pathogens. Rates of heart failure and mortality were similar between patients with CoNS NVE and patients with Staphylococcus aureus NVE, but rates for both groups were significantly higher than rates for patients with NVE due to viridans streptococci. These results emphasize the importance of CoNS as a cause of NVE and the potential for serious complications with this infection.
  •  
53.
  •  
54.
  • Connolly-Andersen, Anne-Marie, et al. (författare)
  • Risk of venous thromboembolism following hemorrhagic fever with renal syndrome : a self-controlled case series study
  • 2018
  • Ingår i: Clinical Infectious Diseases. - : Oxford University Press. - 1058-4838 .- 1537-6591. ; 66:2, s. 268-273
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Bleeding is associated with viral hemorrhagic fevers; however, thromboembolic complications have received less attention. Hemorrhagic fever with renal syndrome (HFRS) is a mild viral hemorrhagic fever caused by Puumala hantavirus. We previously identified HFRS as a risk factor for myocardial infarction and stroke, but the risk for venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is unknown.Methods: Personal identity numbers from the Swedish HFRS database were cross-linked with the National Patient register to obtain information on all causes for hospitalization during 1964 to 2013. The self-controlled case series method was used to calculate the incidence rate ratio (IRR) for first VTE, DVT, and PE during 1998 to 2013.Results: From 7244 HFRS patients, there were 146 with a first VTE of which 74 were DVT and 78 were PE, and 6 patients had both DVT and PE. The overall risk for a VTE was significantly higher during the first 2 weeks following HFRS onset, with an IRR of 64.3 (95% confidence interval [CI], 36.3-114). The corresponding risk for a DVT was 45.9 (95% CI, 18-117.1) and for PE, 76.8 (95% CI, 37.1-159). Sex interacted significantly with the association between HFRS and VTE, with females having a higher risk compared with males.Conclusions: A significantly increased risk for VTE was found in the time period following HFRS onset. It is important to keep this in mind and monitor HFRS patients, and possibly other viral hemorrhagic fever patients, for early symptoms of VTE.
  •  
55.
  •  
56.
  •  
57.
  • Cordonnier, Catherine, et al. (författare)
  • Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation
  • 2009
  • Ingår i: Clinical Infectious Diseases. - : Oxford University Press (OUP). - 1058-4838 .- 1537-6591. ; 48:10, s. 1392-1401
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Invasive pneumococcal disease is a life-threatening complication after allogeneic stem cell transplantation, and at least 20% of cases occur within 1 year after transplantation. The 23-valent pneumococcal polysaccharide vaccine (PPV23) has limited efficacy, especially during the first year after transplantation. The immune response to the conjugated vaccines is expected to be better than that to the polysaccharide vaccine, but the optimal timing of vaccination is not defined. Our objective was to show that a 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) was not inferior when first given 3 months after transplantation, compared with when first given 9 months after transplantation. METHODS: We performed a multicenter, randomized, noninferiority study involving 158 patients from 13 European Group for Blood and Marrow Transplantation centers who were randomly allocated at approximately 100 days after myeloablative stem cell transplantation to receive a series of vaccinations (3 doses of PCV7 given 1 month apart) that was started immediately (i.e., 3 months after transplantation) or 6 months later (i.e., 9 months after transplantation). The primary evaluation criterion was the rate of response (antibody level, > or = 0.15 microg/mL for each of the 7 serotypes) at 1 month after the third dose of PCV7. The noninferiority margin was 20%. All patients were followed up for 24 months after transplantation or until death, whichever occurred first. RESULTS: We found that the response rate was not lower after early vaccination (79% [45 of 57 patients]) than after late vaccination (82% [47 of 57 patients]) (difference, -3.5%; 90% confidence interval, -15.6 to 8.6; not significant). CONCLUSIONS: We conclude that PCV7 vaccination at 3 months after stem cell transplantation is not inferior to PCV7 vaccination at 9 months after transplantation. Because invasive pneumococcal disease can occur early, we recommend starting the PCV7 vaccination series at 3 months after transplantation to ensure earlier protection against Streptococcus pneumoniae. However, the early vaccination may result in only short-lasting response and may not prime for a 23-valent pneumococcal polysaccharide vaccine boost as efficiently as the late vaccination.
  •  
58.
  •  
59.
  • Cresswell, Fiona, V, et al. (författare)
  • High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults : A Phase II Open-Label Randomized Controlled Trial
  • 2021
  • Ingår i: Clinical Infectious Diseases. - : Oxford University Press. - 1058-4838 .- 1537-6591. ; 73:5, s. 876-884
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human immunodeficiency virus (HIV) coinfection, and no cerebrospinal fluid (CSF) PK data exist from Africa. We hypothesized that high-dose rifampicin would increase serum and CSF concentrations without excess toxicity. Methods: In this phase II open-label trial, Ugandan adults with suspected TBM were randomized to standard-of-care control (PO-10, rifampicin 10 mg/kg/day), intravenous rifampicin (IV-20, 20 mg/kg/day), or high-dose oral rifampicin (PO-35, 35 mg/kg/day). We performed PK sampling on days 2 and 14. The primary outcomes were total exposure (AUC(0-24)), maximum concentration (C-max), CSF concentration, and grade 3-5 adverse events. Results: We enrolled 61 adults, 92% were living with HIV, median CD4 count was 50 cells/mu L (interquartile range [IQR] 46-56). On day 2, geometric mean plasma AUC(0-24hr) was 42.9.h mg/L with standard-of-care 10 mg/kg dosing, 249.h mg/L for IV-20 and 327.h mg/L for PO-35 (P<.001). In CSF, standard of care achieved undetectable rifampicin concentration in 56% of participants and geometric mean AUC(0-24hr) 0.27 mg/L, compared with 1.74 mg/L (95% confidence interval [CI] 1.2-2.5) for IV-20 and 2.17 mg/L (1.6-2.9) for PO-35 regimens (P<.001). Achieving CSF concentrations above rifampicin minimal inhibitory concentration (MIC) occurred in 11% (2/18) of standard-of-care, 93% (14/15) of IV-20, and 95% (18/19) of PO-35 participants. Higher serum and CSF levels were sustained at day 14. Adverse events did not differ by dose (P=.34). Conclusions: Current international guidelines result in sub-therapeutic CSF rifampicin concentration for 89% of Ugandan TBM patients. High-dose intravenous and oral rifampicin were safe and respectively resulted in exposures similar to 6- and similar to 8-fold higher than standard of care, and CSF levels above the MIC.
  •  
60.
  • Daley, CL, et al. (författare)
  • Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
  • 2020
  • Ingår i: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. - : Oxford University Press (OUP). - 1537-6591. ; 71:4, s. E1-E36
  • Tidskriftsartikel (refereegranskat)abstract
    • Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 51-60 av 319
Typ av publikation
tidskriftsartikel (315)
forskningsöversikt (4)
Typ av innehåll
refereegranskat (287)
övrigt vetenskapligt/konstnärligt (32)
Författare/redaktör
Ljungman, P (21)
Nord, CE (11)
Norrby-Teglund, A (10)
Ortqvist, A (9)
Rasmussen, Magnus (9)
Reiss, P (7)
visa fler...
Maeurer, M (7)
Cordonnier, C (7)
Mocroft, A (7)
Castagna, A (7)
Sonnerborg, A (6)
Andersson, J (6)
Zumla, A (6)
Giske, CG (6)
Olaison, Lars, 1949 (6)
Günthard, HF (6)
Zangerle, R (6)
Lange, C. (5)
Weintraub, A (5)
Widell, Anders (5)
Gisslén, Magnus, 196 ... (5)
Lindquist, Lars (5)
Linde, A (5)
Petzold, Max, 1973 (5)
Dorlo, Thomas P C (5)
Henriques-Normark, B (5)
Sabin, C. (5)
Singlovic, Jan (5)
Gomes, Melba (5)
Björkman, Per (5)
Ryom, L (5)
Neesgaard, B (5)
Bjorkman, A (4)
aut (4)
Stephan, C (4)
Matteelli, A (4)
Smith, C (4)
Edlund, C (4)
Ajayi, IkeOluwapo O (4)
Nsungwa-Sabiiti, Jes ... (4)
Siribié, Mohamadou (4)
Sermé, Luc (4)
Afonne, Chinenye (4)
Kabarungi, Vanessa (4)
Kyaligonza, Josephin ... (4)
Castellani, Joëlle (4)
Petoumenos, K (4)
Yu, VL (4)
Medstrand, Patrik (4)
Chemaly, RF (4)
visa färre...
Lärosäte
Karolinska Institutet (220)
Uppsala universitet (42)
Lunds universitet (40)
Göteborgs universitet (37)
Umeå universitet (12)
Linköpings universitet (9)
visa fler...
Örebro universitet (6)
Malmö universitet (2)
Södertörns högskola (2)
Chalmers tekniska högskola (2)
Stockholms universitet (1)
Mälardalens universitet (1)
Handelshögskolan i Stockholm (1)
Högskolan Dalarna (1)
Blekinge Tekniska Högskola (1)
visa färre...
Språk
Engelska (319)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (130)
Naturvetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy